The U.S. Food and Drug Administration has approved application ANDA077076, submitted by Bedford, for Lorazepam injectable products.
The approval covers two injectable dosage strengths: 2 mg/mL (product number 001) and 4 mg/mL (product number 002). Both products are currently marked as discontinued in the FDA’s records. The original submission (submission number 1) received approval on July 13, 2005.
Regulatorische Updates27. Sept. 2026•1 Min. Lesezeit
FDA Approves ANDA077076 for Lorazepam Injectable Products
FDA approved ANDA077076 submitted by Bedford for Lorazepam injectable products (2 mg/mL and 4 mg/mL), both listed as discontinued.
Zusammengestellt vom PharmaCountry-Team · Quelle: FDA.gov
Bewertungen
(0)
(0)
(0)
(0)
(0)
Weitere Artikel
Alle Einblicke anzeigenStudien & Berichte
Global Finished Dosage Manufacturing Landscape 2026
5. Okt. 2026
Regulatorische UpdatesKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28. Sept. 2026
AnalysePharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28. Sept. 2026
Bewertung hinterlassen